Kinase-Inhibitors in Iodine-Refractory Differentiated Thyroid Cancer—Focus on Occurrence, Mechanisms, and Management of Treatment-Related Hypertension
Differentiated thyroid cancer (DTC) usually has a good prognosis when treated conventionally with thyroidectomy, radioactive iodine (RAI) and thyroid-stimulating hormone suppression, but some tumors develop a resistance to RAI therapy, requiring alternative treatments. Sorafenib, lenvatinib and cabo...
Guardado en:
Autores principales: | Anne Christine Kaae, Michael C. Kreissl, Marcus Krüger, Manfred Infanger, Daniela Grimm, Markus Wehland |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/d3e7b9e0c59342ffacfd6a407e6d6898 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Pneumatosis intestinalis associated with lenvatinib during thyroid cancer treatment: a case report
por: Soji Toda, et al.
Publicado: (2021) -
Hepatic Arterial Infusion Chemotherapy with Cisplatin versus Sorafenib for Intrahepatic Advanced Hepatocellular Carcinoma: A Propensity Score-Matched Analysis
por: Yuki Zaizen, et al.
Publicado: (2021) -
Acne Inversa-like Lesions Induced by a Low Dose of Sorafenib
por: Javier Aubán-Pariente, et al.
Publicado: (2021) -
Transferrin receptor-targeted HMSN for sorafenib delivery in refractory differentiated thyroid cancer therapy
por: Ke Y, et al.
Publicado: (2018) -
Passive Diffusion vs Active pH-Dependent Encapsulation of Tyrosine Kinase Inhibitors Vandetanib and Lenvatinib into Folate-Targeted Ferritin Delivery System
por: Skubalova Z, et al.
Publicado: (2021)